<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37733626</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>38</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use - Six African Countries, 2021-2023.</ArticleTitle><Pagination><StartPage>1041</StartPage><EndPage>1042</EndPage><MedlinePgn>1041-1042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7238a4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davlantes</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bullard</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Deka</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kfutwah</LastName><ForeName>Anfumbom</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bessaud</LastName><ForeName>Maël</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Lester M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Hawes</LastName><ForeName>Kaija</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Zipursky</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Javier Martin reports institutional support from the Bill &amp; Melinda Gates Foundation. Lester M. Shulman reports support from McKing Consulting Corporation for technical consultation on nOPV2, grant support from the World Health Organization, travel support from the Bill &amp; Melinda Gates Foundation to attend the February 2023 nOPV2 work group meeting in London, and voluntary position as recording secretary for the Israel National Polio Certification Committee and for the Israel Emergency Response Team during 2022–2023. No other potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37733626</ArticleId><ArticleId IdType="pmc">PMC10519714</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7238a4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 2020;27:736–751.e8. 10.1016/j.chom.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Burns CC, Jorba J, et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under Emergency Use Listing—worldwide, March–October 2021. MMWR Morb Mortal Wkly Rep 2022;71:786–90. 10.15585/mmwr.mm7124a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Bandyopadhyay AS, Hoque M, et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet 2023;401:131–9. 10.1016/S0140-6736(22)02397-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02397-2</ArticleId><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="pubmed">36495882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Zipursky S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis 2023;23:e67–71. 10.1016/S1473-3099(22)00582-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00582-5</ArticleId><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Burns CC, Lyons H, et al. Preventing vaccine-derived poliovirus emergence during the polio endgame. PLoS Pathog 2016;12:e1005728. 10.1371/journal.ppat.1005728</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005728</ArticleId><ArticleId IdType="pmc">PMC4934862</ArticleId><ArticleId IdType="pubmed">27384947</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>